Core Insights - Biotricity Inc. has reported significant financial improvements for fiscal year 2025, showcasing a transformation driven by technology and operational efficiencies [2][8][9] Financial Performance - FY25 revenue increased by 14.3% year-over-year to $13.8 million, up from $12.1 million in FY24 [9] - Gross margin improved to 76.6% in FY25, compared to 69.3% in FY24, attributed to increased recurring technology fee revenue and operational efficiencies [8][9] - The net loss for FY25 decreased by 20% year-over-year to $11.9 million, or $0.56 per share, down from a net loss of $14.9 million, or $1.66 per share, in FY24 [9] - Positive Adjusted EBITDA of $438,260 was achieved in Q4 FY25, marking the first time in the company's history to reach EBITDA positivity [8][9] Operational Highlights - Recurring Technology Fees rose by 12% year-over-year to $12.6 million, significantly outpacing Device Sales revenue [7] - Operating expenses were reduced by 24.5% year-over-year, contributing to improved financial metrics [8] - The company is on track to achieve EBITDA breakeven and long-term profitability in FY26 [2][8] Strategic Developments - Biotricity has expanded its Cardiac AI Cloud platform through strategic partnerships, enhancing its market reach to approximately 90% of hospitals in the U.S. [4][3] - The company is pursuing FDA clearance for its AI clinical model, which is expected to revolutionize medical diagnostics and chronic care management [3][4] - Collaborative partnerships established during FY25 and FY26 are aimed at capitalizing on new market channels and value-based care programs [4] Market Position - Biotricity is positioned within a total addressable market of $35 billion, focusing on innovative and accessible cardiac care solutions [15] - The company has secured strategic alliances with three of the top Group Purchasing Organizations (GPOs), representing a significant portion of U.S. hospitals [15]

CARMEL, Ind., July 17, 2025 /PRNewswire/ -- Syra Health (OTCQB: SYRA), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today it has been awarded a new contract with a major insurance provider to staff registered nurses to support specific health plans.Under the one-year agreement, worth up to $2.1 million, Syra Health will provide medical management nurses to work with healthcare providers and plan members. The nurses will as ...

NEW YORK, July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=156860&from=4CLASS PERIOD: April 29, ...

Financial Data and Key Metrics Changes - The IT services revenue for Q1 was $2,590 million, reflecting a 2% decline in constant currency terms, which is within the guidance range [7][20] - Operating margin for Q1 was 17.3%, an expansion of 80 basis points year on year [21] - Net income grew by 10.9% year on year, with earnings per share (EPS) at INR 3.2, a growth of 10.8% year on year [24][25] - Free cash flow as a percentage of net income was robust at 115% for the quarter [25] - The effective tax rate was 21.6% for Q1, down from 24.5% in Q1 2024 [26] Business Line Data and Key Metrics Changes - BFSI sector saw a decline of 3.8% sequentially and 3.5% year on year [23] - Healthcare grew by 0.5% sequentially and 3.5% year on year [23] - Consumer sector declined by 4% sequentially and 5% year on year [23] - Technology and communications grew by 0.4% sequentially but declined by 3% year on year [23] - Capco continued to perform well, growing by 6.1% year on year [24] Market Data and Key Metrics Changes - Americas market grew by 1.5% year on year in constant terms, with strong deal momentum [7] - Europe faced a decline of 6.4% sequentially and 11.6% year on year [22] - Digital spending in India, the Middle East, and Southeast Asia remained resilient [8] Company Strategy and Development Direction - The company is focusing on AI, data, and modernization programs, aligning with client priorities [5][6] - Emphasis on vendor consolidation and cost optimization as key drivers for deal wins [12][45] - The company aims to build an AI-first enterprise, integrating AI capabilities into industry solutions [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding the macro environment, citing ongoing geopolitical uncertainties and tariff impacts [36][100] - Despite uncertainties, there is strong deal momentum in BFSI and technology sectors, with clients focusing on cost optimization and AI investments [37][102] - The outlook for the second half of the year appears positive due to a strong order book and healthy pipeline [18][71] Other Important Information - The board declared an interim dividend of INR 5 per share, distributing over $1,300 million in the last six months [26] - The company revised its capital allocation policy to pay out a minimum of 70% of net income over three years [27] Q&A Session Summary Question: What is the macro outlook right now? - Management acknowledged ongoing uncertainty in the macro environment, with geopolitical issues and tariffs affecting various industries [36] Question: What powered the Americas One performance despite sector declines? - Strong performance in health and communications sectors contributed to the growth in the Americas market unit [39] Question: Is discretionary demand returning? - Discretionary spending is returning in certain areas, particularly around AI and modernization projects [45] Question: How are large deal wins impacting financials? - Large deal wins will take time to ramp up, typically around six to eight quarters, but are expected to positively impact revenues [70] Question: What is the outlook for margins going forward? - Margins may face pressure due to upfront investments required for large deals, but management remains optimistic about maintaining profitability through operational excellence [98]

Financial Data and Key Metrics Changes - IT services revenue for Q1 was $2.59 billion, reflecting a 2% decline in constant currency terms, within guidance range [6][21] - IT services margin was 17.3%, an expansion of 80 basis points year on year [6][22] - Net income grew 10.9% year on year in Q1, with EPS at INR 3.2, a growth of 10.8% year on year [25][26] - Free cash flow as a percentage of net income was robust at 115% for the quarter [26][119] Business Line Data and Key Metrics Changes - BFSI sector saw a decline of 3.8% sequentially and 3.5% year on year, while healthcare grew 0.5% sequentially and 3.5% year on year [24] - Consumer sector declined 4% sequentially and 5% year on year, with technology and communications growing 0.4% sequentially but declining 3% year on year [24] - Capco continued to perform well, growing 6.1% year on year [25] Market Data and Key Metrics Changes - Americas market grew 1.5% year on year in constant terms, with strong deal momentum [6][23] - Europe faced a decline of 6.4% sequentially and 11.6% year on year [23] - Digital spending in India, Middle East, and Southeast Asia remained resilient [6] Company Strategy and Development Direction - Company is focusing on AI, data, and modernization programs, aligning with client priorities [4][5] - Emphasis on vendor consolidation and cost optimization as key drivers for deal wins [11][12] - Company aims to build an AI-first enterprise, integrating AI capabilities into industry solutions [16][17] Management Comments on Operating Environment and Future Outlook - Management expressed caution regarding the macro environment, highlighting ongoing geopolitical uncertainties and tariff impacts [37][39] - Strong order book and healthy pipeline provide confidence for long-term value delivery [18] - Guidance for Q2 indicates a sequential growth range of -1% to +1% in constant currency terms [28] Other Important Information - The board declared an interim dividend of INR 5 per share, distributing over $1.3 billion in cash in the last six months [27][120] - The company revised its capital allocation policy to pay out a minimum of 70% of net income over three years [27] Q&A Session Summary Question: What is the macro outlook right now? - Management acknowledged ongoing uncertainty due to geopolitical factors and tariffs, but noted strong deal momentum in BFSI and technology sectors [37][39] Question: What powered the Americas One performance despite sector declines? - Strong performance in health and communications sectors contributed to the growth in Americas One [40] Question: Is discretionary demand returning? - Discretionary spending is returning in certain pockets, particularly in AI and modernization projects [45] Question: How is AI impacting hiring and headcount changes? - AI efficiency is evolving, and while there is a need for AI-trained talent, the correlation between AI and hiring is not yet strong [48] Question: How are acquired companies contributing to growth? - Capco has performed well, growing 6% year on year, with robust bookings expected to continue [79]

SOMERSET, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, today announced the launch of its fully integrated, AI-driven dermatology EHR, designed to streamline clinical workflows and collections, while enhancing patient engagement and improving financial outcomes for dermatology practices. "Our fully integrated, AI-driven dermatology ...

Core Viewpoint - OptimizeRx Corp. is set to discuss its second quarter financial results for the period ending June 30, 2025, during a conference call scheduled for August 7, 2025 [1][2]. Company Overview - OptimizeRx is a leading healthcare technology company that focuses on connecting life science brands with patients and healthcare providers through innovative solutions [4]. - The company utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to enhance engagement and improve patient outcomes [4]. - OptimizeRx is committed to privacy-safe, patient-centric technology, ensuring impactful interactions that deliver therapies to the right patients at the right time [5]. Conference Call Details - The conference call will take place on August 7, 2025, at 4:30 p.m. Eastern Time, with a question-and-answer session following the management's presentation [2]. - Participants can join the call via toll-free and international numbers, and a webcast will also be available [2]. - A replay of the call will be accessible for 12 months on the company's investor relations website [3].

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open on Thursday, August 7, 2025, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed ...

Johnson & Johnson (JNJ 6.21%) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year. That places it in the elite group of Dividend Kings -- companies with 50 or more consecutive years of increasing their dividend payouts. The healthcare company's payout currently yields 3.3%, more than double the S&P 500's (^GSPC 0.32%) dividend yield (near a record low at around 1.2%). That high-yielding payout is ...

RADNOR, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Centene Corporation (“Centene”) (NYSE: CNC) on behalf of those who purchased or otherwise acquired Centene securities between December 12, 2024, and June 30, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is September 8, 2025. ...